Clinical utility of self-assembling peptide haemostat (PuraBond®) in ENT surgery: a 600-patient observational registry at University Hospitals Birmingham.

IF 1.1 4区医学 Q3 OTORHINOLARYNGOLOGY

Journal of Laryngology and Otology Pub Date : 2026-07-01 DOI:10.1017/S0022215126104988

Asiya Kamber Zaidi, Naomi Tabitha Mohanarajah, Shahzada K Ahmed

{"title":"Clinical utility of self-assembling peptide haemostat (PuraBond®) in ENT surgery: a 600-patient observational registry at University Hospitals Birmingham.","authors":"Asiya Kamber Zaidi, Naomi Tabitha Mohanarajah, Shahzada K Ahmed","doi":"10.1017/S0022215126104988","DOIUrl":null,"url":null,"abstract":"Objectives: This study aimed to evaluate the clinical applications, observed haemostatic outcomes of a self-assembling peptide haemostat (PuraBond®) across a range of ENT surgical procedures using a large UK observational registry.Methods: A two-cycle observational study of 600 patients at University Hospitals Birmingham NHS Foundation Trust (September 2019-July 2024). Data collected included patient demographics, comorbidities, anticoagulation status, surgical details, intra-operative haemostatic outcomes and post-operative complications.Results: Intra-operative haemostasis was documented without the need for additional haemostatic intervention in 99.8% of cases (599/600). Immediate haemostasis-related complication rate was 0.2% (1/600). The overall complication rate was 3% per cent, with most complications unrelated to haemostasis or the use of PuraBond. The study limitations include participant heterogeneity, absence of a control group and small subspeciality sample sizes underscoring the need for comparative studies.Conclusion: This registry demonstrates PuraBond's broad applicability in ENT surgery as an adjunct to routine haemostats and provides essential groundwork for designing future comparative trials.","PeriodicalId":16293,"journal":{"name":"Journal of Laryngology and Otology","volume":" ","pages":"793-799"},"PeriodicalIF":1.1000,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Laryngology and Otology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1017/S0022215126104988","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: This study aimed to evaluate the clinical applications, observed haemostatic outcomes of a self-assembling peptide haemostat (PuraBond®) across a range of ENT surgical procedures using a large UK observational registry.

Methods: A two-cycle observational study of 600 patients at University Hospitals Birmingham NHS Foundation Trust (September 2019-July 2024). Data collected included patient demographics, comorbidities, anticoagulation status, surgical details, intra-operative haemostatic outcomes and post-operative complications.

Results: Intra-operative haemostasis was documented without the need for additional haemostatic intervention in 99.8% of cases (599/600). Immediate haemostasis-related complication rate was 0.2% (1/600). The overall complication rate was 3% per cent, with most complications unrelated to haemostasis or the use of PuraBond. The study limitations include participant heterogeneity, absence of a control group and small subspeciality sample sizes underscoring the need for comparative studies.

Conclusion: This registry demonstrates PuraBond's broad applicability in ENT surgery as an adjunct to routine haemostats and provides essential groundwork for designing future comparative trials.

查看原文本刊更多论文

自组装肽止血剂（PuraBond®）在耳鼻喉外科中的临床应用：伯明翰大学医院600名患者的观察登记。

目的：本研究旨在评估自组装肽止血剂（PuraBond®）在一系列耳鼻喉外科手术中的临床应用和观察到的止血效果。方法：对2019年9月- 2024年7月伯明翰大学医院NHS基金会信托基金的600例患者进行两周期观察研究。收集的数据包括患者人口统计、合并症、抗凝状态、手术细节、术中止血结果和术后并发症。结果：99.8%的病例（599/600）术中止血，无需额外止血干预。即刻出血相关并发症发生率为0.2%（1/600）。总的并发症发生率为3%，大多数并发症与止血或使用PuraBond无关。研究的局限性包括参与者的异质性、缺乏对照组和亚专业样本量小，强调了比较研究的必要性。结论：该注册证明PuraBond在耳鼻喉科手术中作为常规止血剂的辅助手段具有广泛的适用性，并为设计未来的比较试验提供了必要的基础。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Laryngology and Otology 医学-耳鼻喉科学

CiteScore

3.20

自引率

11.80%

发文量

593

审稿时长

3-6 weeks

期刊介绍： The Journal of Laryngology & Otology (JLO) is a leading, monthly journal containing original scientific articles and clinical records in otology, rhinology, laryngology and related specialties. Founded in 1887, JLO is absorbing reading for ENT specialists and trainees. The journal has an international outlook with contributions from around the world, relevant to all specialists in this area regardless of the country in which they practise. JLO contains main articles (original, review and historical), case reports and short reports as well as radiology, pathology or oncology in focus, a selection of abstracts, book reviews, letters to the editor, general notes and calendar, operative surgery techniques, and occasional supplements. It is fully illustrated and has become a definitive reference source in this fast-moving subject area. Published monthly an annual subscription is excellent value for money. Included in the subscription is access to the JLO interactive web site with searchable abstract database of the journal archive back to 1887.